287 related articles for article (PubMed ID: 35303381)
1. Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease.
Wang Y; Abrol R; Mak JYW; Das Gupta K; Ramnath D; Karunakaran D; Fairlie DP; Sweet MJ
FEBS J; 2023 Jun; 290(11):2805-2832. PubMed ID: 35303381
[TBL] [Abstract][Full Text] [Related]
2. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling.
Sinnett-Smith J; Ni Y; Wang J; Ming M; Young SH; Rozengurt E
Am J Physiol Cell Physiol; 2014 May; 306(10):C961-71. PubMed ID: 24647541
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase Hdac7 supports LPS-inducible glycolysis and Il-1β production in murine macrophages via distinct mechanisms.
Ramnath D; Das Gupta K; Wang Y; Abrol R; Curson JEB; Lim J; Reid RC; Mansell A; Blumenthal A; Karunakaran D; Fairlie DP; Sweet MJ
J Leukoc Biol; 2022 Feb; 111(2):327-336. PubMed ID: 34811804
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages.
Shakespear MR; Hohenhaus DM; Kelly GM; Kamal NA; Gupta P; Labzin LI; Schroder K; Garceau V; Barbero S; Iyer A; Hume DA; Reid RC; Irvine KM; Fairlie DP; Sweet MJ
J Biol Chem; 2013 Aug; 288(35):25362-25374. PubMed ID: 23853092
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases as regulators of inflammation and immunity.
Shakespear MR; Halili MA; Irvine KM; Fairlie DP; Sweet MJ
Trends Immunol; 2011 Jul; 32(7):335-43. PubMed ID: 21570914
[TBL] [Abstract][Full Text] [Related]
8. Class IIa Histone Deacetylases Drive Toll-like Receptor-Inducible Glycolysis and Macrophage Inflammatory Responses via Pyruvate Kinase M2.
Das Gupta K; Shakespear MR; Curson JEB; Murthy AMV; Iyer A; Hodson MP; Ramnath D; Tillu VA; von Pein JB; Reid RC; Tunny K; Hohenhaus DM; Moradi SV; Kelly GM; Kobayashi T; Gunter JH; Stevenson AJ; Xu W; Luo L; Jones A; Johnston WA; Blumenthal A; Alexandrov K; Collins BM; Stow JL; Fairlie DP; Sweet MJ
Cell Rep; 2020 Feb; 30(8):2712-2728.e8. PubMed ID: 32101747
[TBL] [Abstract][Full Text] [Related]
9. Natural products as zinc-dependent histone deacetylase inhibitors.
Tan S; Liu ZP
ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
[TBL] [Abstract][Full Text] [Related]
10. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
11. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
Li Z; Zhu WG
Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
[TBL] [Abstract][Full Text] [Related]
12. A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease.
Wright LH; Menick DR
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H199-206. PubMed ID: 27208161
[TBL] [Abstract][Full Text] [Related]
13. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
14. Non-sirtuin histone deacetylases in the control of cardiac aging.
Ferguson BS; McKinsey TA
J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
[TBL] [Abstract][Full Text] [Related]
15. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.
Bai G; Wei D; Zou S; Ren K; Dubner R
Mol Pain; 2010 Sep; 6():51. PubMed ID: 20822541
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
18. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA
Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983
[TBL] [Abstract][Full Text] [Related]
19. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylases in cardiovascular and metabolic diseases.
Bagchi RA; Weeks KL
J Mol Cell Cardiol; 2019 May; 130():151-159. PubMed ID: 30978343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
